

Funding Opportunities July 2025

Sponsor	Program	Limit	Maximum Award Amount	Application Deadline
Novo Nordisk, Evotec, and Johns Hopkins University	Novo Nordisk and Evotec LAB eN² – Johns Hopkins University Collaboration	\$4,000,000	Rolling basis	About two months
Francis Family Foundation	Parker B. Francis Fellowship Program	2 per department	\$25,000	8/5/2025
The Greenwall Foundation	Greenwall Faculty Scholars Program	1	50% salary for 3 years, 10% IDC, \$5,000/year travel and project support	8/5/2025
NIH	NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Not Allowed) PAR-23-286	4 (1 per scientific area, combined with PAR-23-287 and PAR-23-288)	Salary & other program expenses	8/19/2025
NIH	NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Required) PAR-23-287	4 (1 per scientific area, combined with PAR-23-286 and PAR-23-288)	Salary & other program expenses	8/19/2025
NIH	NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 – Independent Basic Experimental Studies with Humans Required) PAR-23-288	4 (1 per scientific area, combined with PAR-23-286 and PAR-23-287)	Salary & other program expenses	8/19/2025
Merkin Peripheral Neuropathy and Nerve Regeneration Center	Seed Grants	\$150,000	August 31, 2025	TBD
Johns Hopkins Urban Health	Strategic Consultation Grants for Baltimore City		\$10,000	Rolling basis TBD
Office of the Vice Provost for Research	President's Frontier Award	\$300,000	September 1, 2025	TBD
NIH	RFA-CA-24-006 Translational Research Toward Development of a Kaposi			9/8/2025

	Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional) AIDS - New/Renewal/Resubmission/Revision, as allowed:			
Specialized Ovarian Cancer Research SPORE (Specialized Programs of Research Excellence)	Development Research Awards & Career Enhancement Awards	\$50,000 (direct costs)	October 1, 2025	TBD
NIH	PAR-23-22 HIV/AIDS Scholars Using Nonhuman Primate (NHP) Models Program (K01) Standard AIDS			1/8/2026
NIH	PAR-23-073 Mentored Career Development Program for Early Stage Investigators Using Nonhuman Primate Research Models (K01)			5/8/2026
Merkin Peripheral Neuropathy and Nerve Regeneration Center	Micro Grants	\$20,000	Rolling basis through July 1, 2026	Within 4 weeks
Office of the Vice Provost for Research	JHU Pivot Grants	\$150,000	Rolling basis	TBD
NIH	White House Initiative on Women's Health Research			11/5/2027
The Hopkins CFAR	CFAR Small Grants Program		5/18/2027	rolling within 4 weeks of application
Johns Hopkins School of Medicine	Tilghman Traveling Fellowship		1/24/2021	Rolling basis
The Ignite Fund	The Ignite Fund		Typically, \$1,000	Rolling basis

Upcoming Deadlines for Fogarty Funding Opportunities

- [Global Infectious Diseases](#)
Application deadline: August 6, 2025
- [International Research Scientist Development Award \(IRSDA\)](#)
Application deadline: March 9, 2026
- [Mobile Health \(mHealth\)](#)
Application deadline: March 20, 2026



[Upcoming deadlines for all Fogarty funding opportunities](#)

Funding opportunities on which Fogarty is a partner:

- [Dissemination and Implementation Research in Health \(R03 Clinical Trial Not Allowed\)](#) (PAR-25-233)
Application due date: Multiple dates, see announcement.
- [Dissemination and Implementation Research in Health \(R21 Clinical Trial Optional\)](#) (PAR-25-143)
Application due date: Multiple dates, see announcement.

Administrative supplements for current Fogarty grant recipients:

- [Administrative Supplements to Promote Research Continuity and Retention of NIH Mentored Career Development \(K\) Award Recipients and Scholars](#) (NOT-OD-23-031)
Expiration date: October 1, 2025
 - [Administrative Supplement for Continuity of Biomedical and Behavioral Research Among First-Time Recipients of NIH Research Project Grant Awards](#) (NOT-OD-23-032)
Expiration date: October 1, 2025
-  [All administrative supplements](#)

NIH funding opportunities focusing on global health and foreign collaboration:

- [Notice of Special Interest: Administrative Supplements for the U.S.-Japan Brain Research Cooperative Program \(BRCP\) - U.S. Entity \(Admin Supp\)](#) (NOT-NS-23-092)
Application due date: September 19, 2025
 - [Pragmatic Trials across the Cancer Control Continuum \(UG3/UH3 Clinical Trial Required\)](#) (PAR-25-072)
Application due date: October 17, 2025
-  [More NIH funding opportunities focused on areas relevant to global health](#)

NIH funding opportunities for which foreign organizations and/or foreign components of U.S. organizations may apply:

- [Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases \(R01 Clinical Trials Optional\)](#) (RFA-FD-25-017)
Application Receipt Date(s): Multiple dates, see announcement.
- [Reissue of RFA-FD-23-001- Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases \(R01 Clinical Trials Required\)](#) (RFA-FD-25-020)
Application Receipt Date(s): Multiple dates, see announcement.

NIH funding opportunities for which foreign components may apply:

- [Single Source: National Centralized Repository for Alzheimer's Disease and Related Dementias \(NCRAD\) \(U24 Clinical Trial Not Allowed\)](#) (RFA-AG-26-002)
Application Receipt Date(s): October 17, 2025



National Heart, Lung,
and Blood Institute

July 2025

Division of Lung Diseases Updates

Funding opportunities, program updates, and job openings in the NHLBI Division of Lung Diseases.

Viral INfections in the Young Lung- The VINYL Clinical Consortium (UG3/UH3 Clinical Trial Optional) and Data and Analytics Co-ordinating Center (U24 Clinical Trial Optional)

The National Heart, Lung and Blood Institute (NHLBI) intends to publish a Notice of Funding Opportunity (NOFO) which will support a consortium to phenotype 0–2-year-old children with severe viral lower respiratory tract infections (LRTI) with follow up until pre-school age for pulmonary sequelae. This Forecasted Opportunity has been updated from the original NHLBI Notice of intent to publish (NOT-HL-24-027) and the links below are being provided to allow potential applicants sufficient time to develop responsive projects. NHLBI intends to utilize the U24 to fund the Data and Analytics Co-ordinating Center (DACC) and the linked UG3/UH3 (Phased award with built-in milestones for transition) to fund one Clinical Coordinating Center (CCC) and Biorepository along with four Clinical Centers (CCs).

For more information, please see below and/or contact Marrah Lachowicz-Scroggins at marrah.lachowicz-scroggins@nih.gov.

- [FOR-HL-25-032 Viral INfections in the Young Lung- The VINYL Clinical Consortium \(UG3/UH3 Clinical Trial Optional\)](#)
- [FOR-HL-25-033 Viral INfections in the Young Lung- The VINYL Clinical Consortium- Data Analytics and Coordinating Center \(DACC\) \(U24 Clinical Trial Optional\)](#)

Maternal and Perinatal Nutritional Programming of Lung Health in Childhood and Early Adulthood: Research Gaps and Opportunities Workshop: Executive Summary Now Available

NHLBI hosted a two-day virtual workshop entitled “Maternal and Perinatal Nutritional Programming of Lung Health in Childhood and Early Adulthood: Research Gaps and Opportunities” on October 24–25, 2024. Attendees included basic scientists, maternal-fetal medicine (MFM) experts, neonatologists, pulmonologists, nutrition experts, nurses, implementation scientists, and other multidisciplinary researchers. Presenters discussed the role of maternal and perinatal nutrition on lung health across the lifespan to identify critical research gaps, challenges, and opportunities to promote health, as well as disease prevention and management. The workshop executive summary which includes an overview of the discussions of the five sessions: 1) Prenatal nutrition and lung disease, 2) Perinatal and postnatal nutrition and lung disease, 3) Biomarkers and mediators of lung disease, 4) Links between nutrition, prematurity, and bronchopulmonary dysplasia with childhood and adult lung function; and 5) Food is medicine programs, as well as a summary of research gaps and emerging opportunities within the field, has now been published can now be found at [Maternal and Perinatal Nutritional Programming of Lung Health in Childhood and Early Adulthood: Research Gaps and Opportunities | NHLBI, NIH](#).

RFA-OD-25-008: Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional)

NIH in conjunction with the Food and Drug Administration (FDA) has published this Notice of Funding Opportunity (NOFO) to support new biomedical, behavioral, and social science investigators who are in the early stages of establishing independent careers in tobacco regulatory research. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies, secondary analysis of existing data, small, self-contained research projects, development of research methodology, and development of new research technology. Applicants are encouraged to conduct projects that ultimately have the potential to inform regulations on tobacco product manufacturing, distribution, and marketing. Research projects must address one or more High-Priority Research Topic(s) related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the [Family Smoking Prevention and Tobacco Control Act \(FSPTCA\)](#), Public Law 111-31. The awards under this NOFO will be administered by NIH using funds made available through FDA CTP and the FSPTCA. Research results from this NOFO are expected to generate findings and data directly relevant to informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.

For more information regarding Program Scope, Research Objectives and High-Priority Research Topics please see:

[RFA-OD-25-008: Tobacco Regulatory Science Small Grant Program for New Investigators \(R03 Clinical Trial Optional\)](#) and/or contact qing.lu@nih.gov.

To learn more about previous research and other funding opportunities related to the NIH -FDA partnership to foster tobacco regulatory research please visit the Tobacco Regulatory Science Program website at [Tobacco Regulatory Science | Prevention Research | ODP](#).

Ruth L. Kirschstein National Research Service Award (NRSA) Notices of Funding Opportunities

The overall goal of the NIH Ruth L. Kirschstein National Research Service Award (NRSA) program is to help ensure that a diverse pool of highly trained scientists is available in appropriate scientific disciplines to address the Nation's biomedical, behavioral, and clinical research needs. NRSA fellowships support the training of pre-and postdoctoral scientists, dual-degree investigators, and senior researchers. The NRSA "F Series" offers research training and career development at varying career levels. Opportunities are available to individuals and institutions who aim to advance NHLBI-related science. These fellowships may provide a stipend, institutional allowance to help support the costs of training, tuition and fees, and childcare costs. Please see the recently reissued list of funding opportunities that NHLBI participates in below.

Please also note that as of January 25, 2025, NIH has revised the application and review criteria for fellowship applications. Applicants are strongly encouraged to visit [Revisions to the NIH Fellowship Application and Review Process | Grants & Funding](#) and the accompanying [Frequently Asked Questions](#) page prior to submitting.

- [Ruth L. Kirschstein National Research Service Award \(NRSA\) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs \(Parent F30\)](#)
PA-25-426 | Released June 12, 2025

- [Ruth L. Kirschstein National Research Service Award \(NRSA\) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs \(Parent F30\)](#)
PA-25-425 | Released June 12, 2025
- [Ruth L. Kirschstein National Research Service Award \(NRSA\) Individual Postdoctoral Fellowship \(Parent F32\)](#)
PA-25-423 | Released June 12, 2025
- [Ruth L. Kirschstein National Research Service Award \(NRSA\) Individual Predoctoral Fellowship \(Parent F31\)](#)
PA-25-422 | Released June 12, 2025
- [Ruth L. Kirschstein National Research Service Award \(NRSA\) Individual Senior Fellowship \(Parent F33\)](#)
PA-25-424 | Released June 12, 2025

More information about NRSA programs may be found at the [NIH Research Training and Career Development](#) website. (NOTE: This is a new website. Please update your bookmarks)

Applicants interested in NHLBI individual fellowships are also encouraged to visit [Training and Career Development | NHLBI, NIH](#).

NHLBI Updated Guidelines for Program Project Grant Applications

The National Heart, Lung, and Blood Institute has a long history of supporting investigator-initiated team science through program project grants (PPGs). NHLBI has recently published a Frequently Asked Question page to highlight current and updated policies and guidelines for PPG applicants.

Effective for the November 2025 scientific review cycle, Program Project Grant (PPG) applications will be reviewed by the NIH Center for Scientific Review (CSR). As a result, the review of P01 applications may differ from the process originally described in [PAR-24-065](#). Applicants are encouraged to examine their ERA Commons account for review assignment and contact information. This information will appear two weeks after the submission due date.

For more information please visit [Guidelines for Program Project Grants | NHLBI, NIH](#).

Notice of Extensions

Early-Stage Investigator (ESI) Eligibility

NIH released NOT-OD-25-114 to grant an automatic extension of Early-Stage Investigator (ESI) eligibility. This extension addresses delays impacting grant application submissions, peer review, or award processing timelines between January 1, 2025, and May 31, 2025, and seeks to mitigate their effects on the biomedical

research community. Potential applicants are encouraged to see the link below to determine who is impacted and the criteria for determining eligibility for the extension.

[Notice of Short-Term Extension to Early-Stage Investigator \(ESI\) Eligibility Period](#)

NOT-OD-25-114 | Released May 21, 2025

NIH Pathway to Independence Award (K99/R00)

NIH released NOT-OD-25-121 to announce an extension until October/November 2025 receipt dates for prospective applicants to the NIH Pathway to Independence Award (K99/R00) program. The extension is limited to individuals whose eligibility period under the Parent K99/R00 would have ended between October 2024 – January 2026. Potential applicants are encouraged to see the link below to determine who is impacted and the criteria for determining eligibility for the extension.

[Temporary Extension of Eligibility for the NIH Pathway to Independence Award \(K99/R00\)](#)

NOT-OD-25-121 | Released May 21, 2025

NHLBI has also released the following notices of extensions for the following NOFO's. The expiration dates for the PAR's listed below has been extended to January 2026.

PAR-25-309 “Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)”

[PAR-25-029](#) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. Trials for which this NOFO applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see [NOT-OD-15-015](#)). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the [NHLBI website](#). Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact listed at the bottom of the notice prior to submitting an application.

[Notice of Extension to PAR-25-029 "Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials \(Collaborative UG3/UH3 Clinical Trial Required\)](#)

NOT-HL-25-012 | Released May 21, 2025

PAR-22-193 “Notice of Extension to PAR-22-193 "Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)”

[PAR-22-193](#) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see [NOT-OD-15-015](#)). Both a DCC application and a

collaborating CCC application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.

[Notice of Extension to PAR-22-193 "Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials \(Collaborative U24 Clinical Trial Required\)"](#)

NOT-HL-25-014 | Released May 21, 2025

PAR-25-028 "Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)"

[PAR-25-028](#) supports applications to develop and implement investigator-initiated single-site clinical trials. Clinical trials supported by this NOFO include Phase II and above clinical trials. This NOFO is applicable to single-site clinical trials only and will utilize a bi-phasic (R61/R33), milestone-driven mechanism consisting of a start-up phase of up to one year (R61), and a full enrollment and clinical trial execution phase of up to four years (R33). Proposed research may utilize a design anywhere along the continuum of efficacy, effectiveness, pragmatic and/or implementation research clinical trials. For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the [NHLBI website](#).

[Notice of Extension to PAR-25-028 "Single-Site Investigator-Initiated Clinical Trials \(R61/R33 Clinical Trial Required\)"](#)

NOT-HL-25-011 | Released May 21, 2025

Other Funding Opportunities of Interest

[Rare Diseases Clinical Research Consortia \(RDCRC\) for the Rare Diseases Clinical Research Network \(RDCRN\) \(U54 Clinical Trial Optional\)](#)

PAR-25-438 | Released June 06, 2025

[Notice of Correction to RFA-HL-26-014 NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases \(R44 Clinical Trial Optional\)](#)

NOT-HL-25-006 | Released May 14, 2025

[Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences \(R25 Clinical Trials Not Allowed\)](#)

RFA-OD-25-003 | Released January 21, 2025

[Multidisciplinary Studies of HIV/AIDS and Aging \(R01 Clinical Trial Optional\)](#)

PAR-25-354 | Released January 08, 2025

[Multidisciplinary Studies of HIV/AIDS and Aging \(R21 Clinical Trial Optional\)](#)

PAR-25-355 | Released January 08, 2025

Request for Proposals (RFP)

PARP-Inhibitor Combination Treatments: Biomarker Testing, Safety, and Efficacy in a Rapidly Changing Metastatic Prostate Cancer (mPC) Landscape

Pfizer External Research & Grants (ER&G) (formerly Global Medical Grants & Partnerships) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's ER&G competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

Date RFP Issued: June 26, 2025

Geographic Scope: United States

Clinical Area: Oncology – Genitourinary

Link to full RFP: [PARP-Inhibitor Combination Treatments: Biomarker Testing, Safety, and Efficacy in a Rapidly Changing Metastatic Prostate Cancer \(mPC\) Landscape](#)

Application Due Date: August 21, 2025

Specific Area of Interest: Projects that will be considered for Pfizer support will focus on increasing healthcare professional knowledge and competence in the following areas:

- Guideline concordance and best practices for integration of testing into clinical practice, including: when to order testing and how to interpret results of biomarkers and genetic mutations (inclusive of all HRR mutations, i.e. BRCA and non-BRCA), the role of the multidisciplinary team in ordering tests, and education on strategies to identify and remove barriers to appropriate testing for patients with prostate cancer.
- Emerging data on efficacy and safety regarding PARPi's used in the treatment of mPC including better understanding of: 1) the mechanism of action and the biological and clinical rationale for PARPi combinations and; 2) clinical safety, treatment sequencing and patient subgroup data
- Clinical data regarding PARPi combinations and how to mitigate associated side effects for optimal patient care, including but not limited to, the role of the multidisciplinary team in ongoing therapy management.

- Best practices for initiating guideline concordant care for patients with mPC in community healthcare settings for optimal therapy management of PARPi combinations in prostate cancer including but not limited to, implementation of genetic testing workflows and encouraging patient engagement in treatment decisions and clinical trial participation.